Inflectra (Infliximab) ( DrugBank: Infliximab )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 95 | Autoimmune hepatitis | 1 |
95. Autoimmune hepatitis
Clinical trials : 52 / Drugs : 68 - (DrugBank : 28) / Drug target genes : 19 - Drug target pathways : 112
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2017-003311-19-DE (EUCTR) | 09/01/2018 | 18/09/2017 | Phase IIa proof-of-principle study for the induction treatment of autoimmune hepatitis using infliximabAIH-MAB | Phase IIa proof-of-principle study for the induction treatment of autoimmune hepatitis using infliximabAIH-MAB | Autoimmune Hepatitis (AIH); rare inflammatory liver disease associated with elevated transaminases, elevated Immunoglobulin G, the presence of autoantibodies and interface hepatitis in liver histology. Untreated, AIH progresses to liver fibrosis and cirrhosis with its complications. Historical placebo-controlled studies could show a mortality of around 70% in the placebo-treated group.;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: Inflectra (Infliximab) | University Medical Centre Hamburg-Eppendorf | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 12 | Phase 2 | Germany |